Glaucoma and Alzheimer’s Disease in the Elderly

• Guo L , SaltTE, LuongVet al. Targeting amyloid-β in glaucoma treatment. Proc. Natl Acad. Sci. USA 104(33), 13444–13449(2007).
   PubMed Web of Science ®Google Scholar
• Parisi V . Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer‘s disease. Semin. Ophthalmol.18(2), 50–57(2003).
   PubMedGoogle Scholar
• Guo L , DugganJ, CordeiroMF. Alzheimer‘s disease and retinal neurodegeneration. Curr. Alzheimer Res.7(1), 3–14(2010).
   PubMed Web of Science ®Google Scholar
• Wostyn P , AudenaertK, De Deyn PP. Alzheimer‘s disease and glaucoma: is there a causal relationship? Br. J. Ophthalmol.93(12), 1557–1559(2009).
   PubMed Web of Science ®Google Scholar
• Kountouras J , ZavosC, GavalasE, BozikiM, ChatzopoulosD, KatsinelosP. Normal-tension glaucoma and Alzheimer‘s disease: Helicobacter pylori as a possible common underlying risk factor. Med. Hypotheses68(1), 228–229(2007).
   PubMed Web of Science ®Google Scholar
• Bayer AU , FerrariF, ErbC. High occurrence rate of glaucoma among patients with Alzheimer‘s disease. Eur. Neurol.47(3), 165–168(2002).
   PubMed Web of Science ®Google Scholar
• Tamura H , KawakamiH, KanamotoTet al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer‘s disease. J. Neurol. Sci. 246(1–2), 79–83(2006).
   PubMed Web of Science ®Google Scholar
• McKinnon SJ . Glaucoma: ocular Alzheimer‘s disease? Front. Biosci.8, S1140–S1156 (2003).
   PubMed Web of Science ®Google Scholar
• Wostyn P , AudenaertK, De Deyn PP. Alzheimer‘s disease: cerebral glaucoma? Med. Hypotheses74(6), 973–977(2010).
   PubMed Web of Science ®Google Scholar
• Quigley HA , BromanAT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol.90(3), 262–267(2006).
   PubMed Web of Science ®Google Scholar
• Friedman DS , WolfsRC, O‘ColmainBJet al. Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol. 122(4), 532–538(2004).
   PubMedGoogle Scholar
• Rein DB , ZhangP, WirthKEet al. The economic burden of major adult visual disorders in the United States. Arch. Ophthalmol. 124(12), 1754–1760(2006).
   PubMedGoogle Scholar
• Friedman DS , JampelHD, MunozB, WestSK. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch. Ophthalmol.124(11), 1625–1630(2006).
   PubMedGoogle Scholar
• Wang YX , XuL, YangH, JonasJB. Prevalence of glaucoma in north China: the Beijing Eye Study. Am. J. Ophthalmol.150(6), 917–924(2010).
   PubMed Web of Science ®Google Scholar
• Czudowska MA , RamdasWD, WolfsRCet al. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam study. Ophthalmology 117(9), 1705–1712(2010).
   PubMed Web of Science ®Google Scholar
• Bramley T , PeeplesP, WaltJG, JuhaszM, HansenJE. Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma. Arch. Ophthalmol.126(6), 849–856(2008).
   PubMedGoogle Scholar
• Blennow K , De Leon MJ, Zetterberg H. Alzheimer‘s disease. Lancet368(9533), 387–403(2006).
   PubMed Web of Science ®Google Scholar
• Ferri CP , PrinceM, BrayneCet al. Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503), 2112–2117(2005).
   PubMed Web of Science ®Google Scholar
• Serrano-Aguilar PG , Lopez-BastidaJ, Yanes-LopezV. Impact on health-related quality of life and perceived burden of informal caregivers of individuals with Alzheimer‘s disease. Neuroepidemiology27(3), 136–142(2006).
   PubMed Web of Science ®Google Scholar
• Connell CM , JanevicMR, GallantMP. The costs of caring: impact of dementia on family caregivers. J. Geriatr. Psychiatry Neurol.14(4), 179–187(2001).
   PubMed Web of Science ®Google Scholar
• Brookmeyer R , JohnsonE, Ziegler-GrahamK, ArrighiHM. Forecasting the global burden of Alzheimer‘s disease. Alzheimers Dement.3(3), 186–191(2007).
   PubMed Web of Science ®Google Scholar
• Comas-Herrera A , WittenbergR, PickardL, KnappM. Cognitive impairment in older people: future demand for long-term care services and the associated costs. Int. J. Geriatr. Psychiatry22(10), 1037–1045(2007).
   PubMed Web of Science ®Google Scholar
• Bayer AU , FerrariF. Severe progression of glaucomatous optic neuropathy in patients with Alzheimer‘s disease. Eye (Lond.)16(2), 209–212(2002).
   PubMed Web of Science ®Google Scholar
• Kessing LV , LopezAG, AndersenPK, KessingSV. No increased risk of developing Alzheimer disease in patients with glaucoma. J. Glaucoma16(1), 47–51(2007).
   PubMed Web of Science ®Google Scholar
• Bach-Holm D , KessingSV, MogensenU, FormanJL, AndersenPK, KessingLV. Normal tension glaucoma and Alzheimer disease: comorbidity? Acta Ophthalmol. DOI: 10.1111/j.1755-3768.2011.02125.x (2011) (Epub ahead of print).
   Google Scholar
• Kwon YH , FingertJH, KuehnMH, AlwardWL. Primary open-angle glaucoma. N. Engl. J. Med.360(11), 1113–1124(2009).
   PubMed Web of Science ®Google Scholar
• Dahlmann-Noor AH , VijayS, LimbGA, KhawPT. Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies. Drug Discov. Today15(7–8), 287–299(2010).
   PubMed Web of Science ®Google Scholar
• Anderson DR . Normal-tension glaucoma (Low-tension glaucoma). Indian J. Ophthalmol. (Suppl. 59), S97–S101 (2011).
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol.126(4), 498–505(1998).
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K , BrigattiL, WeitzmanM, CaprioliJ. Outcomes of trabeculectomy for primary open-angle glaucoma. Ophthalmology102(12), 1760–1769(1995).
   PubMed Web of Science ®Google Scholar
• Kotecha A , SprattA, BunceC, Garway-HeathDF, KhawPT, ViswanathanA. Optic disc and visual field changes after trabeculectomy. Invest. Ophthalmol. Vis. Sci.50(10), 4693–4699(2009).
   PubMed Web of Science ®Google Scholar
• Gupta N , WeinrebRN. New definitions of glaucoma. Curr. Opin. Ophthalmol.8(2), 38–41(1997).
   PubMedGoogle Scholar
• Baltmr A , DugganJ, NizariS, SaltTE, CordeiroMF. Neuroprotection in glaucoma – is there a future role? Exp. Eye Res.91(5), 554–566(2010).
   PubMed Web of Science ®Google Scholar
• Quigley HA , DunkelbergerGR, GreenWR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am. J. Ophthalmol.107(5), 453–464(1989).
   PubMed Web of Science ®Google Scholar
• Dubois B , FeldmanHH, JacovaCet al. Research criteria for the diagnosis of Alzheimer‘s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734–746(2007).
   PubMed Web of Science ®Google Scholar
• Li S , ShankarGM, SelkoeDJ. How do soluble oligomers of amyloid β-protein impair hippocampal synaptic plasticity? Front. Cell. Neurosci.4, 5 (2010).
   PubMedGoogle Scholar
• Hardy JA , HigginsGA. Alzheimer‘s disease: the amyloid cascade hypothesis. Science256(5054), 184–185(1992).
   PubMed Web of Science ®Google Scholar
• Normando EM , CoxonKM, GuoL, CordeiroMF. Focus on: amyloid β. Exp. Eye Res.89(4), 446–447(2009).
   PubMed Web of Science ®Google Scholar
• Goate A , Chartier-HarlinMC, MullanMet al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer‘s disease. Nature 349(6311), 704–706(1991).
   PubMed Web of Science ®Google Scholar
• Chartier-Harlin MC , CrawfordF, HouldenHet al. Early-onset Alzheimer‘s disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353(6347), 844–846(1991).
   PubMed Web of Science ®Google Scholar
• Hyman BT , Gomez-IslaT, WestHet al. Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer‘s disease. Window on molecular epidemiology. Ann. NY Acad. Sci. 777, 158–165(1996).
   PubMed Web of Science ®Google Scholar
• Shankar GM , LiS, MehtaTHet al. Amyloid-β protein dimers isolated directly from Alzheimer‘s brains impair synaptic plasticity and memory. Nat. Med. 14(8), 837–842(2008).
   PubMed Web of Science ®Google Scholar
• Haass C , SelkoeDJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer‘s amyloid β-peptide. Nat. Rev. Mol. Cell. Biol.8(2), 101–112(2007).
   PubMed Web of Science ®Google Scholar
• Cheng IH , Scearce-LevieK, LegleiterJet al. Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282(33), 23818–23828(2007).
   PubMed Web of Science ®Google Scholar
• Lue LF , KuoYM, RoherAEet al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer‘s disease. Am. J. Pathol. 155(3), 853–862(1999).
   PubMed Web of Science ®Google Scholar
• Holmes C , BocheD, WilkinsonDet al. Long-term effects of Aβ42 immunisation in Alzheimer‘s disease: follow-up of a randomised, placebo-controlled Phase I trial. Lancet 372(9634), 216–223(2008).
   PubMed Web of Science ®Google Scholar
• McKinnon SJ , LehmanDM, Kerrigan-BaumrindLAet al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest. Ophthalmol. Vis. Sci. 43(4), 1077–1087(2002).
   PubMed Web of Science ®Google Scholar
• Kipfer-Kauer A , McKinnonSJ, FruehBE, GoldblumD. Distribution of amyloid precursor protein and amyloid-β in ocular hypertensive C57BL/6 mouse eyes. Curr. Eye Res.35(9), 828–834(2010).
   PubMed Web of Science ®Google Scholar
• Goldblum D , Kipfer-KauerA, SarraGM, WolfS, FruehBE. Distribution of amyloid precursor protein and amyloid-β immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest. Ophthalmol. Vis. Sci.48(11), 5085–5090(2007).
   PubMed Web of Science ®Google Scholar
• Esch FS , KeimPS, BeattieECet al. Cleavage of amyloid β peptide during constitutive processing of its precursor. Science 248(4959), 1122–1124(1990).
   PubMed Web of Science ®Google Scholar
• Kim TW , PettingellWH, JungYK, KovacsDM, TanziRE. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science277(5324), 373–376(1997).
   PubMed Web of Science ®Google Scholar
• Yoneda S , HaraH, HirataA, FukushimaM, InomataY, TaniharaH. Vitreous fluid levels of β-amyloid((1–42)) and tau in patients with retinal diseases. Jpn. J. Ophthalmol.49(2), 106–108(2005).
   PubMed Web of Science ®Google Scholar
• Blennow K , HampelH, WeinerM, ZetterbergH. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol.6(3), 131–144(2010).
   PubMed Web of Science ®Google Scholar
• Strozyk D , BlennowK, WhiteLR, LaunerLJ. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology60(4), 652–656(2003).
   PubMed Web of Science ®Google Scholar
• Cordeiro MF , GuoL, LuongVet al. Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc. Natl Acad. Sci. USA 101(36), 13352–13356(2004).
   PubMed Web of Science ®Google Scholar
• Tsuruma K , TanakaY, ShimazawaM, HaraH. Induction of amyloid precursor protein by the neurotoxic peptide, amyloid-β 25–35, causes retinal ganglion cell death. J. Neurochem.113(6), 1545–1554(2010).
   PubMed Web of Science ®Google Scholar
• Perez SE , LumayagS, KovacsB, MufsonEJ, XuS. β-amyloid deposition and functional impairment in the retina of the APPswe/PS1δE9 transgenic mouse model of Alzheimer‘s disease. Invest. Ophthalmol. Vis. Sci.50(2), 793–800(2009).
   PubMed Web of Science ®Google Scholar
• Liu B , RasoolS, YangZet al. Amyloid-peptide vaccinations reduce {β}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer‘s transgenic mice. Am. J. Pathol. 175(5), 2099–2110(2009).
   PubMed Web of Science ®Google Scholar
• Koronyo-Hamaoui M , KoronyoY, LjubimovAVet al. Identification of amyloid plaques in retinas from Alzheimer‘s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 54(Suppl. 1), S204–S217 (2011).
   PubMed Web of Science ®Google Scholar
• Ning A , CuiJ, ToE, AsheKH, MatsubaraJ. Amyloid-β deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest. Ophthalmol. Vis. Sci.49(11), 5136–5143(2008).
   PubMed Web of Science ®Google Scholar
• Cordeiro MF , GuoL, CoxonKMet al. Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo. Cell. Death Dis. 1(1), e3 (2010).
   PubMedGoogle Scholar
• Glodzik L , De Santi S, Tsui WH et al. Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol. Aging DOI: 10.1016/j.neurobiolaging.2009.12.026 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Gasparini L , CrowtherRA, MartinKRet al. Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability. Neurobiol. Aging 32(3), 419–433(2009).
   PubMed Web of Science ®Google Scholar
• Tseng HKL , ProiaA, McKinnonS. Expression of protein markers of Alzheimer‘s disease in human glaucoma eyes. ARVO Meeting Abstracts48, 3269 (2007).
   Google Scholar
• Gupta N , FongJ, AngLC, YucelYH. Retinal tau pathology in human glaucomas. Can. J. Ophthalmol.43(1), 53–60(2008).
   PubMed Web of Science ®Google Scholar
• Hinton DR , SadunAA, BlanksJC, MillerCA. Optic-nerve degeneration in Alzheimer‘s disease. N. Engl. J. Med.315(8), 485–487(1986).
   PubMed Web of Science ®Google Scholar
• Sadun AA , BassiCJ. Optic nerve damage in Alzheimer‘s disease. Ophthalmology97(1), 9–17(1990).
   PubMed Web of Science ®Google Scholar
• Kirby E , BandelowS, HogervorstE. Visual impairment in Alzheimer‘s disease: a critical review. J. Alzheimers Dis.21(1), 15–34(2010).
   PubMed Web of Science ®Google Scholar
• Blanks JC , HintonDR, SadunAA, MillerCA. Retinal ganglion cell degeneration in Alzheimer‘s disease. Brain Res.501(2), 364–372(1989).
   PubMed Web of Science ®Google Scholar
• Blanks JC , SchmidtSY, TorigoeY, PorrelloKV, HintonDR, BlanksRH. Retinal pathology in Alzheimer‘s disease. II. Regional neuron loss and glial changes in GCL. Neurobiol. Aging17(3), 385–395(1996).
   PubMed Web of Science ®Google Scholar
• Danesh-Meyer HV , BirchH, KuJY, CarrollS, GambleG. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology67(10), 1852–1854(2006).
   PubMed Web of Science ®Google Scholar
• Nickells RW . Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Surv. Ophthalmol.43(Suppl. 1), S151–S161 (1999).
   PubMed Web of Science ®Google Scholar
• Quigley HA , KatzJ, DerickRJ, GilbertD, SommerA. An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage. Ophthalmology99(1), 19–28(1992).
   PubMed Web of Science ®Google Scholar
• Guo L , NormandoEM, NizariS, LaraD, CordeiroMF. Tracking longitudinal retinal changes in experimental ocular hypertension using the cSLO and spectral domain-OCT. Invest. Ophthalmol. Vis. Sci.51(12), 6504–6513(2010).
   PubMed Web of Science ®Google Scholar
• Parisi V , RestucciaR, FattappostaF, MinaC, BucciMG, PierelliF. Morphological and functional retinal impairment in Alzheimer‘s disease patients. Clin. Neurophysiol.112(10), 1860–1867(2001).
   PubMed Web of Science ®Google Scholar
• Iseri PK , AltinasO, TokayT, YukselN. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J. Neuroophthalmol.26(1), 18–24(2006).
   PubMed Web of Science ®Google Scholar
• Paquet C , BoissonnotM, RogerF, DighieroP, GilR, HugonJ. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer‘s disease. Neurosci. Lett.420(2), 97–99(2007).
   PubMed Web of Science ®Google Scholar
• Berisha F , FekeGT, TrempeCL, McMeelJW, SchepensCL. Retinal abnormalities in early Alzheimer‘s disease. Invest. Ophthalmol. Vis. Sci.48(5), 2285–2289(2007).
   PubMed Web of Science ®Google Scholar
• Lu Y , LiZ, ZhangXet al. Retinal nerve fiber layer structure abnormalities in early Alzheimer‘s disease: evidence in optical coherence tomography. Neurosci. Lett. 480(1), 69–72(2010).
   PubMed Web of Science ®Google Scholar
• Katz B , RimmerS, IraguiV, KatzmanR. Abnormal pattern electroretinogram in Alzheimer‘s disease: evidence for retinal ganglion cell degeneration? Ann. Neurol.26(2), 221–225(1989).
   PubMed Web of Science ®Google Scholar
• Trick GL , BarrisMC, Bickler-BluthM. Abnormal pattern electroretinograms in patients with senile dementia of the Alzheimer type. Ann. Neurol.26(2), 226–231(1989).
   PubMed Web of Science ®Google Scholar
• Kergoat H , KergoatMJ, JustinoL, ChertkowH, RobillardA, BergmanH. Visual retinocortical function in dementia of the Alzheimer type. Gerontology48(4), 197–203(2002).
   PubMed Web of Science ®Google Scholar
• Krasodomska K , LubinskiW, PotemkowskiA, HonczarenkoK. Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer‘s disease. Doc. Ophthalmol.121(2), 111–121(2010).
   PubMed Web of Science ®Google Scholar
• Sommer A , KatzJ, QuigleyHAet al. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch. Ophthalmol. 109(1), 77–83(1991).
   PubMedGoogle Scholar
• Quigley HA , AddicksEM, GreenWR. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch. Ophthalmol.100(1), 135–146(1982).
   PubMedGoogle Scholar
• Curcio CA , DruckerDN. Retinal ganglion cells in Alzheimer‘s disease and aging. Ann. Neurol.33(3), 248–257(1993).
   PubMed Web of Science ®Google Scholar
• Davies DC , McCoubrieP, McDonaldB, JobstKA. Myelinated axon number in the optic nerve is unaffected by Alzheimer‘s disease. Br. J. Ophthalmol.79(6), 596–600(1995).
   PubMed Web of Science ®Google Scholar
• Tsai CS , RitchR, SchwartzBet al. Optic nerve head and nerve fiber layer in Alzheimer‘s disease. Arch. Ophthalmol. 109(2), 199–204(1991).
   PubMedGoogle Scholar
• Yucel Y , GuptaN. Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration. Prog. Brain Res.173, 465–478(2008).
   PubMed Web of Science ®Google Scholar
• Bertram L , TanziRE. Thirty years of Alzheimer‘s disease genetics: the implications of systematic meta-analyses. Nat. Rev. Neurosci.9(10), 768–778(2008).
   PubMed Web of Science ®Google Scholar
• Ressiniotis T , GriffithsPG, BirchM, KeersS, ChinneryPF. The role of apolipoprotein E gene polymorphisms in primary open-angle glaucoma. Arch. Ophthalmol.122(2), 258–261(2004).
   PubMedGoogle Scholar
• Lam CY , FanBJ, WangDYet al. Association of apolipoprotein E polymorphisms with normal tension glaucoma in a Chinese population. J. Glaucoma 15(3), 218–222(2006).
   PubMed Web of Science ®Google Scholar
• Saglar E , YucelD, BozkurtB, OzgulRK, IrkecM, OgusA. Association of polymorphisms in APOE, p53, and p21 with primary open-angle glaucoma in Turkish patients. Mol. Vis.15, 1270–1276(2009).
   PubMed Web of Science ®Google Scholar
• Al-Dabbagh NM , Al-DohayanN, ArfinM, TariqM. Apolipoprotein E polymorphisms and primary glaucoma in Saudis. Mol. Vis.15, 912–919(2009).
   PubMed Web of Science ®Google Scholar
• Zetterberg M , TasaG, PalmerMSet al. Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 143(6), 1059–1060(2007).
   PubMed Web of Science ®Google Scholar
• Lake S , LiveraniE, DesaiMet al. Normal tension glaucoma is not associated with the common apolipoprotein E gene polymorphisms. Br. J. Ophthalmol. 88(4), 491–493(2004).
   PubMed Web of Science ®Google Scholar
• Mabuchi F , TangS, AndoDet al. The apolipoprotein E gene polymorphism is associated with open angle glaucoma in the Japanese population. Mol. Vis. 11, 609–612(2005).
   PubMed Web of Science ®Google Scholar
• Garcia AN , MunizMT, Souza e Silva HR, Da Silva HA, Athayde-Junior L. Cyp46 polymorphisms in Alzheimer‘s disease: a review. J. Mol. Neurosci.39(3), 342–345(2009).
   PubMed Web of Science ®Google Scholar
• Fourgeux C , MartineL, BjorkhemIet al. Primary open-angle glaucoma: association with cholesterol 24S-hydroxylase (CYP46A1) gene polymorphism and plasma 24-hydroxycholesterol levels. Invest. Ophthalmol. Vis. Sci. 50(12), 5712–5717(2009).
   PubMed Web of Science ®Google Scholar
• Mossbock G , WegerM, FaschingerCet al. Role of cholesterol 24S-hydroxylase gene polymorphism (rs754203) in primary open angle glaucoma. Mol. Vis. 17, 616–620(2011).
   PubMed Web of Science ®Google Scholar
• Silverberg G , MayoM, SaulT, FellmannJ, McguireD. Elevated cerebrospinal fluid pressure in patients with Alzheimer‘s disease. Cerebrospinal Fluid Res.3, 7 (2006).
   PubMedGoogle Scholar
• Wostyn P , AudenaertK, De Deyn PP. More advanced Alzheimer‘s disease may be associated with a decrease in cerebrospinal fluid pressure. Cerebrospinal Fluid Res.6, 14 (2009).
   PubMedGoogle Scholar
• Berdahl JP , AllinghamRR, JohnsonDH. Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma. Ophthalmology115(5), 763–768(2008).
   PubMed Web of Science ®Google Scholar
• Ren R , JonasJB, TianGet al. Cerebrospinal fluid pressure in glaucoma: a prospective study. Ophthalmology 117(2), 259–266(2010).
   PubMed Web of Science ®Google Scholar
• Hayreh SS . Cerebrospinal fluid pressure and glaucomatous optic disc cupping. Graefes Arch. Clin. Exp. Ophthalmol.247(6), 721–724(2009).
   PubMed Web of Science ®Google Scholar
• The EUROGAST Study Group. Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut34(12), 1672–1676(1993).
   PubMed Web of Science ®Google Scholar
• Ozturk FKE , Inan Üü, Çetinkaya Z, Altindis M. Is Helicobacter pylori related to glaucoma? In: Program and Abstracts of the 6th Congress of the European Glaucoma Society. London, UK, 26–29 June 2000.
   Google Scholar
• Kountouras JMN , BouraP, BessasC, ChatzopoulosD, VenizelosJZC. Relationship between Helicobacter pylori infection and glaucoma. In: Program and Abstracts of the 6th Congress of the European Glaucoma Society. London, UK, 26–29 June 2000.
   Google Scholar
• Kountouras J , MylopoulosN, BouraPet al. Relationship between Helicobacter pylori infection and glaucoma. Ophthalmology 108(3), 599–604(2001).
   PubMed Web of Science ®Google Scholar
• Kountouras J , MylopoulosN, ChatzopoulosDet al. Eradication of Helicobacter pylori may be beneficial in the management of chronic open-angle glaucoma. Arch. Intern. Med. 162(11), 1237–1244(2002).
   PubMedGoogle Scholar
• Deshpande N , LalithaP, Krishna Das SR et al.Helicobacter pylori IgG antibodies in aqueous humor and serum of subjects with primary open angle and pseudo-exfoliation glaucoma in a South Indian population. J. Glaucoma17(8), 605–610(2008).
   PubMed Web of Science ®Google Scholar
• Kim JM , KimSH, ParkKH, HanSY, ShimHS. Investigation of the association between Helicobacter pylori infection and normal tension glaucoma. Invest. Ophthalmol. Vis. Sci.52(2), 665–668(2011).
   PubMed Web of Science ®Google Scholar
• Hong YZC , DuanL, WangW. Relationship between Helicobacter pylori infection and open angle glaucoma in China. Asian J. Ophthalmol.9(5), 205–208(2007).
   Google Scholar
• Galloway PH , WarnerSJ, MorshedMG, MikelbergFS. Helicobacter pylori infection and the risk for open-angle glaucoma. Ophthalmology110(5), 922–925(2003).
   PubMed Web of Science ®Google Scholar
• Kurtz S , RegenbogenM, GoldinerI, HorowitzN, MoshkowitzM. No association between Helicobacter pylori infection or CagA-bearing strains and glaucoma. J. Glaucoma17(3), 223–226(2008).
   PubMed Web of Science ®Google Scholar
• Kountouras J , MylopoulosN, KonstasAG, ZavosC, ChatzopoulosD, BouklaA. Increased levels of Helicobacter pylori IgG antibodies in aqueous humor of patients with primary open-angle and exfoliation glaucoma. Graefes Arch. Clin. Exp. Ophthalmol.241(11), 884–890(2003).
   PubMed Web of Science ®Google Scholar
• Razeghinejad Mr K -SE, Farvardin M, Pourhabibi A. Aqueous levels of anti-Helicobacter pylori IgG antibody in patients with primary open angle and pseudoexfoliation glaucoma. Iran J. Immunol.3(2), 86–90(2006).
   Google Scholar
• Öztürk FKE , InanU, ErmisS, ÇetinkayaZ, AltindisM. Is there a relationship between glaucoma and Helicobacter pylori? African J. Microbiol. Res.3(9), 560–564(2009).
   Google Scholar
• Malaguarnera M , BellaR, AlagonaG, FerriR, CarnemollaA, PennisiG. Helicobacter pylori and Alzheimer‘s disease: a possible link. Eur. J. Intern. Med.15(6), 381–386(2004).
   PubMedGoogle Scholar
• Kountouras J , BozikiM, GavalasEet al. Increased cerebrospinal fluid Helicobacter pylori antibody in Alzheimer‘s disease. Int. J. Neurosci. 119(6), 765–777(2009).
   PubMed Web of Science ®Google Scholar
• Kountouras J , TsolakiM, GavalasEet al. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology 66(6), 938–940(2006).
   PubMed Web of Science ®Google Scholar
• Kountouras J , BozikiM, GavalasEet al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer‘s disease. J. Neurol. 256(5), 758–767(2009).
   PubMed Web of Science ®Google Scholar
• Kountouras J , BozikiM, GavalasEet al. Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Cogn. Behav. Neurol. 23(3), 199–204(2010).
   PubMed Web of Science ®Google Scholar
• Lemere CA , MasliahE. Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nat. Rev. Neurol.6(2), 108–119(2010).
   PubMed Web of Science ®Google Scholar
• Chow VW , SavonenkoAV, MelnikovaTet al. Modeling an anti-amyloid combination therapy for Alzheimer‘s disease. Sci. Transl. Med. 2(13), 13ra1 (2010).
   PubMed Web of Science ®Google Scholar
• Prins ND , VisserPJ, ScheltensP. Can novel therapeutics halt the amyloid cascade? Alzheimers Res. Ther.2(2), 5 (2010).
   PubMedGoogle Scholar
• Mangialasche F , SolomonA, WinbladB, MecocciP, KivipeltoM. Alzheimer‘s disease: clinical trials and drug development. Lancet Neurol.9(7), 702–716(2010).
   PubMed Web of Science ®Google Scholar
• Golde TE , PetrucelliL, LewisJ. Targeting Aβ and tau in Alzheimer‘s disease, an early interim report. Exp. Neurol.223(2), 252–266(2010).
   PubMed Web of Science ®Google Scholar
• Schneider A , MandelkowE. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics5(3), 443–457(2008).
   PubMed Web of Science ®Google Scholar
• Doody RS , StevensJC, BeckCet al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56(9), 1154–1166(2001).
   PubMed Web of Science ®Google Scholar
• Contestabile A . The history of the cholinergic hypothesis. Behav. Brain Res.221(2), 334–340(2011).
   PubMed Web of Science ®Google Scholar
• Birks J . Cholinesterase inhibitors for Alzheimer‘s disease. Cochrane Database Syst. Rev.1, CD005593 (2006).
   PubMed Web of Science ®Google Scholar
• Sugiyama T , UtsunomiyaK, OtaH, OguraY, NarabayashiI, IkedaT. Comparative study of cerebral blood flow in patients with normal-tension glaucoma and control subjects. Am. J. Ophthalmol.141(2), 394–396(2006).
   PubMed Web of Science ®Google Scholar
• Yoshida Y , SugiyamaT, UtsunomiyaK, OguraY, IkedaT. A pilot study for the effects of donepezil therapy on cerebral and optic nerve head blood flow, visual field defect in normal-tension glaucoma. J. Ocul. Pharmacol. Ther.26(2), 187–192(2010).
   PubMed Web of Science ®Google Scholar
• Estermann S , DaeppGC, Cattapan-LudewigK, BerkhoffM, FruehBE, GoldblumD. Effect of oral donepezil on intraocular pressure in normotensive Alzheimer patients. J. Ocul. Pharmacol. Ther.22(1), 62–67(2006).
   PubMed Web of Science ®Google Scholar
• Almasieh M , ZhouY, KellyME, CasanovaC, Di Polo A. Structural and functional neuroprotection in glaucoma role of galantamine-mediated activation of muscarinic acetylcholine receptors. Cell Death Dis.1(2), e27 (2010).
   PubMedGoogle Scholar
• Maragos WF , GreenamyreJT, PenneyJB Jr, Young AB. Glutamate dysfunction in Alzheimer‘s disease: an hypothesis. Trends Neurosci.10(2), 65–68(1987).
   Web of Science ®Google Scholar
• Lipton SA . The molecular basis of memantine action in Alzheimer‘s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res.2(2), 155–165(2005).
   PubMedGoogle Scholar
• Brito-Moreira J , Paula-LimaAC, BomfimTRet al. Aβ oligomers induce glutamate release from hippocampal neurons. Curr. Alzheimer Res. 8(5), 552–562(2011).
   PubMed Web of Science ®Google Scholar
• De Felice FG , VelascoPT, LambertMPet al. Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282(15), 11590–11601(2007).
   PubMed Web of Science ®Google Scholar
• Chen Y , DurakoglugilMS, XianX, HerzJ. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc. Natl Acad. Sci. USA107(26), 12011–12016(2010).
   PubMed Web of Science ®Google Scholar
• Robinson DM , KeatingGM. Memantine: a review of its use in Alzheimer‘s disease. Drugs66(11), 1515–1534(2006).
   PubMed Web of Science ®Google Scholar
• Lipton SA . Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr. Drug Targets8(5), 621–632(2007).
   PubMed Web of Science ®Google Scholar
• Danysz W , ParsonsCG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer‘s disease: preclinical evidence. Int. J. Geriatr. Psychiatry18(Suppl. 1), S23–S32 (2003).
   PubMedGoogle Scholar
• Wilcock GK . Memantine for the treatment of dementia. Lancet Neurol.2(8), 503–505(2003).
   PubMed Web of Science ®Google Scholar
• Areosa SA , SherriffF, McShaneR. Memantine for dementia. Cochrane Database Syst. Rev.3, CD003154 (2005).
   PubMedGoogle Scholar
• Tariot PN , FarlowMR, GrossbergGT, GrahamSM, McDonaldS, GergelI. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA291(3), 317–324(2004).
   PubMed Web of Science ®Google Scholar
• Guo L , SaltTE, MaassAet al. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest. Ophthalmol. Vis. Sci. 47(2), 626–633(2006).
   PubMed Web of Science ®Google Scholar
• Dreyer EB , ZurakowskiD, SchumerRA, PodosSM, LiptonSA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol.114(3), 299–305(1996).
   PubMed Web of Science ®Google Scholar
• Brooks DE , GarciaGA, DreyerEB, ZurakowskiD, Franco-BourlandRE. Vitreous body glutamate concentration in dogs with glaucoma. Am. J. Vet. Res.58(8), 864–867(1997).
   PubMed Web of Science ®Google Scholar
• Pellegrini JW , LiptonSA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann. Neurol.33(4), 403–407(1993).
   PubMed Web of Science ®Google Scholar
• Schuettauf F , QuintoK, NaskarR, ZurakowskiD. Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model. Vision Res.42(20), 2333–2337(2002).
   PubMed Web of Science ®Google Scholar
• Kim TW , KimDM, ParkKH, KimH. Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia. Korean J. Ophthalmol.16(1), 1–7(2002).
   PubMedGoogle Scholar
• Woldemussie E , YolesE, SchwartzM, RuizG, WheelerLA. Neuroprotective effect of memantine in different retinal injury models in rats. J. Glaucoma11(6), 474–480(2002).
   PubMed Web of Science ®Google Scholar
• Hare WA , WoldemussieE, LaiRKet al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest. Ophthalmol. Vis. Sci. 45(8), 2625–2639(2004).
   PubMed Web of Science ®Google Scholar
• Hare WA , WoldemussieE, WeinrebRNet al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Invest. Ophthalmol. Vis. Sci. 45(8), 2640–2651(2004).
   PubMed Web of Science ®Google Scholar
• Yucel YH , GuptaN, ZhangQ, MizisinAP, KalichmanMW, WeinrebRN. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch. Ophthalmol.124(2), 217–225(2006).
   PubMedGoogle Scholar
• Sena DF , RamchandK, LindsleyK. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst. Rev.2, CD006539 (2010).
   PubMedGoogle Scholar
• Kato T . Memantine: a therapeutic drug for Alzheimer‘s disease and the comparison with MK-801. Nippon Yakurigaku Zasshi124(3), 145–151(2004).
   PubMedGoogle Scholar
• Russelakis-Carneiro M , SilveiraLC, PerryVH. Factors affecting the survival of cat retinal ganglion cells after optic nerve injury. J. Neurocytol.25(6), 393–402(1996).
   PubMedGoogle Scholar
• Solberg Y , RosnerM, TuretzJ, BelkinM. MK-801 has neuroprotective and antiproliferative effects in retinal laser injury. Invest. Ophthalmol. Vis. Sci.38(7), 1380–1389(1997).
   PubMed Web of Science ®Google Scholar
• Chaudhary P , AhmedF, SharmaSC. MK801-a neuroprotectant in rat hypertensive eyes. Brain Res.792(1), 154–158(1998).
   PubMed Web of Science ®Google Scholar
• Tsuda K . Neuroprotective effects of MK-801 and catecholamine release in the central nervous system. Stroke35(5), e96 (2004).
   PubMedGoogle Scholar
• Citron M . Alzheimer‘s disease: strategies for disease modification. Nat. Rev. Drug Discov.9(5), 387–398(2010).
   PubMed Web of Science ®Google Scholar
• Tatton W , ChenD, Chalmers-RedmanR, WheelerL, NixonR, TattonN. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer‘s disease: anti-apoptosis by α-2-adrenergic receptor activation. Surv. Ophthalmol.48(Suppl. 1), S25–S37 (2003).
   PubMed Web of Science ®Google Scholar
• Wostyn P . Normal-tension glaucoma and Alzheimer‘s disease: hypothesis of a possible common underlying risk factor. Med. Hypotheses67(5), 1255–1256(2006).
   PubMed Web of Science ®Google Scholar

Website

• Centers for Disease Control and Prevention (CDC), 2010. www.cdc.gov/NCHS/data/nvsr/nvsr58/nvsr58_19.pdf
   Google Scholar